GlassScriptPhysician profile
Edmond K Chu
NPI 1013975838
$24,507.74
in general payments reported to CMS, 2019-2025
42 companies · $3,414 in 2025
The $3,414 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,915 · 2020: $1,762 · 2021: $3,391 · 2022: $3,116 · 2023: $3,660 · 2024: $4,250 · 2025: $3,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,323.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,258.75 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $2,580.83 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $2,225.07 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,142.30 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,988.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,178.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,119.12 | 2019-2025 | Repatha, Evenity, Repatha |
| Gilead Sciences, INC. | $1,040.00 | 2019-2024 | Vemlidy, Epclusa |
| Abbvie INC. | $758.03 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $597.67 | 2019-2025 | |
| Amarin Pharma, INC. | $449.89 | 2019-2021 | |
| Corcept Therapeutics | $337.68 | 2023-2024 | Korlym |
| Abbott Laboratories | $297.96 | 2022-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $262.04 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $238.28 | 2024 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.